Emmanuel Mahe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emmanuel Mahe has a total of 959 co-authors. Here are the top co-authors by number of shared publications:
A. Beauchet
Department of Public Health, Hôpital Raymond Poincaré, 104 Bd Raymond Poincaré, 92380 Garches, France
22 shared publicationsM.-L. Sigal
Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel-Prud'hon, 95100 Argenteuil, France
13 shared publications- Sebastien Barbarot
Department of Dermatology Nantes University Hospital Nantes France
13 shared publications C. Sin
Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France
11 shared publicationsF. Maccari
Cabinet libéral, 3, avenue de Chanzy, 94210 La Varenne-Saint-Hilaire, France
11 shared publications- Marie-Aleth Richard
Dermatology Department, CEReSS‐EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, University Hospital Timone, Assistance Publique Hôpitaux de Marseille Marseille France
10 shared publications
Latest Publications
- 15 November 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 34 (2) , 105619
Use of focused clinical audits in pediatric teledermatology for optimizing service delivery: Lessons from a Franco-African store-and-forward network
- 15 November 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 34 (2) , 105619
Use of focused clinical audits in pediatric teledermatology for optimizing service delivery: Lessons from a Franco-African store-and-forward network
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- 9 July 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (9)
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.
- 6 July 2026
- Published by Wiley in Pediatric Dermatology
Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort
Background: In childhood, moderate‐to‐severe psoriasis often requires systemic treatments such as acitretin, methotrexate, or cyclosporine. This study aimed to explore the feasibility of discontinuing systemic therapy in pediatric patients who achieve remission when receiving these treatments and to identify predictors of sustained remission. Methods: The ACMe cohort study was a retrospective, multicenter, international, real‐world study involving children and adolescents with moderate‐to‐severe psoriasis treated with acitretin, methotrexate, or cyclosporine. Patients who achieved remission and stopped their systemic treatment were monitored for up to 6 months to evaluate the need for further systemic treatment. Results: Of the 433 patients analyzed, 79 (18.2%) discontinued systemic treatment due to remission. Of these, 70 (88.6%) remained off systemic treatment for at least 6 months. Factors predictive of discontinuation due to remission included younger age (9.0 ± 3.5 vs. 10.5 ± 4.1 years, p < 0.001); lower baseline psoriasis severity (PGA: 3.0 ± 0.7 vs. 3.3 ± 0.8; and PASI: 9.3 ± 4.8 vs. 11.1 ± 6.8, p < 0.04); and the presence of non‐palmoplantar forms of psoriasis (palmoplantar psoriasis : 5 (6.3%) vs. 58 (16.4%), p = 0.02). No factors were identified that predicted sustained remission at 6 months. Conclusions: These promising results suggest that systemic treatment discontinuation during clinical remission is feasible for pediatric patients with moderate‐to‐severe psoriasis and is associated with a low risk of early relapse. Prospective studies with long‐term follow‐up are needed to confirm the durability of remission and to better define criteria for selecting candidates for treatment discontinuation.
- 6 July 2026
- Published by Wiley in Pediatric Dermatology
Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort
Background: In childhood, moderate‐to‐severe psoriasis often requires systemic treatments such as acitretin, methotrexate, or cyclosporine. This study aimed to explore the feasibility of discontinuing systemic therapy in pediatric patients who achieve remission when receiving these treatments and to identify predictors of sustained remission. Methods: The ACMe cohort study was a retrospective, multicenter, international, real‐world study involving children and adolescents with moderate‐to‐severe psoriasis treated with acitretin, methotrexate, or cyclosporine. Patients who achieved remission and stopped their systemic treatment were monitored for up to 6 months to evaluate the need for further systemic treatment. Results: Of the 433 patients analyzed, 79 (18.2%) discontinued systemic treatment due to remission. Of these, 70 (88.6%) remained off systemic treatment for at least 6 months. Factors predictive of discontinuation due to remission included younger age (9.0 ± 3.5 vs. 10.5 ± 4.1 years, p < 0.001); lower baseline psoriasis severity (PGA: 3.0 ± 0.7 vs. 3.3 ± 0.8; and PASI: 9.3 ± 4.8 vs. 11.1 ± 6.8, p < 0.04); and the presence of non‐palmoplantar forms of psoriasis (palmoplantar psoriasis : 5 (6.3%) vs. 58 (16.4%), p = 0.02). No factors were identified that predicted sustained remission at 6 months. Conclusions: These promising results suggest that systemic treatment discontinuation during clinical remission is feasible for pediatric patients with moderate‐to‐severe psoriasis and is associated with a low risk of early relapse. Prospective studies with long‐term follow‐up are needed to confirm the durability of remission and to better define criteria for selecting candidates for treatment discontinuation.
- Open Access
- 23 April 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 928-932
Residual Disease in Adult Psoriasis‐Treated Patients: Frequency, Clinical Aspects, and Management. A Survey Among Dermatologists
Background: In moderate‐to‐severe psoriasis, residual lesions can be defined as “psoriasis lesions that persist despite well‐managed treatment, and which do not necessarily justify intensification or a change in treatment.” Residual lesions are accepted by guidelines and clinical trials. Objectives: The aim of this study was to evaluate the knowledge, identified risk factors, and management of residual psoriasis lesions among dermatologists. Methods: We performed a web‐based survey among French dermatologists between December 2024 and January 2025. Results: Among the 505 (21.0% of surveyed dermatologists) responders, 30.7% stated that the limit between “treatment ineffectiveness” and “residual disease” was unclear, and 88.6% declared to see patients with residual lesions. The profile of patients with residual lesions was middle‐age patients (30–70 years: > 56% of treated patients), males (97.0%), with incomplete treatment efficacy (67.7%), long‐standing psoriasis (47.6%), and past history of severe psoriasis (41.2%). Main identified locations were scalp (50.6%), elbows (48.3%), nails (43.0%), shins (40.0%), and knees (35.9%). One quarter (22.5%) of dermatologists declared not to anticipate treatment of residual disease. Conclusions: In everyday practice, residual psoriasis in patients undergoing systemic treatment is a reality and a major concern for dermatologists and patients, especially as, according to guidelines and clinical trials, incomplete treatment efficacy is tolerated.
- 23 April 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 928-932
Open AccessResidual Disease in Adult Psoriasis‐Treated Patients: Frequency, Clinical Aspects, and Management. A Survey Among Dermatologists
Background: In moderate‐to‐severe psoriasis, residual lesions can be defined as “psoriasis lesions that persist despite well‐managed treatment, and which do not necessarily justify intensification or a change in treatment.” Residual lesions are accepted by guidelines and clinical trials. Objectives: The aim of this study was to evaluate the knowledge, identified risk factors, and management of residual psoriasis lesions among dermatologists. Methods: We performed a web‐based survey among French dermatologists between December 2024 and January 2025. Results: Among the 505 (21.0% of surveyed dermatologists) responders, 30.7% stated that the limit between “treatment ineffectiveness” and “residual disease” was unclear, and 88.6% declared to see patients with residual lesions. The profile of patients with residual lesions was middle‐age patients (30–70 years: > 56% of treated patients), males (97.0%), with incomplete treatment efficacy (67.7%), long‐standing psoriasis (47.6%), and past history of severe psoriasis (41.2%). Main identified locations were scalp (50.6%), elbows (48.3%), nails (43.0%), shins (40.0%), and knees (35.9%). One quarter (22.5%) of dermatologists declared not to anticipate treatment of residual disease. Conclusions: In everyday practice, residual psoriasis in patients undergoing systemic treatment is a reality and a major concern for dermatologists and patients, especially as, according to guidelines and clinical trials, incomplete treatment efficacy is tolerated.
- 10 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 38-47
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomized clinical trial
Background: Superpotent topical corticosteroids (STS) are highly effective in bullous pemphigoid (BP), but prolonged use is associated with practical limitations and a risk of relapse. Objectives: To evaluate whether combining short-term STS with methotrexate (MTX) could maintain efficacy, reduce relapses and preserve safety compared with prolonged STS alone. Methods: In this multicentre randomized open-label noninferiority trial, adults with BP were assigned to receive either STS (clobetasol propionate) for 1 month plus low-dose MTX as maintenance (MTX + STS arm), or prolonged STS alone (STS arm). The primary endpoint was 9-month overall survival (OS), with a predefined noninferiority margin of 15%. Secondary outcomes included relapse-free survival (RFS) and serious adverse events (SAEs). Results: Among 266 randomized patients (mean age 80.8 years), 9-month OS was 86.5% in the MTX + STS arm and 83.5% in the STS arm [P = 0.498; hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.40–1.50]. The lower limit of the 90% CI for the difference in survival rates (−4.6%) remained within the predefined noninferiority margin, meeting the primary endpoint. Among the 87.4% of patients who achieved disease control within 28 days, relapse occurred in 31 patients in the MTX + STS arm and 52 in the STS arm, corresponding to a 9-month RFS of 68.4% (95% CI 59.3–78.8) vs. 47.4% (95% CI 37.7–59.5), respectively (P = 0.042). SAEs were more frequent in the MTX + STS arm than in the STS arm [mean number per patient per month 0.40 (95% CI 0.23–0.57) vs. 0.19 (95% CI 0.01–0.36), P = 0.005]. One limitation of this study was its open-label design. Moreover, it did not include a validated disease activity score and was conducted in a selected BP population managed under clinical trial conditions. Conclusions: Maintenance therapy with low-dose MTX is noninferior to prolonged STS in terms of survival and is associated with a reduced risk of relapse, at the cost of increased toxicity.
- 10 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 38-47
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomized clinical trial
Background: Superpotent topical corticosteroids (STS) are highly effective in bullous pemphigoid (BP), but prolonged use is associated with practical limitations and a risk of relapse. Objectives: To evaluate whether combining short-term STS with methotrexate (MTX) could maintain efficacy, reduce relapses and preserve safety compared with prolonged STS alone. Methods: In this multicentre randomized open-label noninferiority trial, adults with BP were assigned to receive either STS (clobetasol propionate) for 1 month plus low-dose MTX as maintenance (MTX + STS arm), or prolonged STS alone (STS arm). The primary endpoint was 9-month overall survival (OS), with a predefined noninferiority margin of 15%. Secondary outcomes included relapse-free survival (RFS) and serious adverse events (SAEs). Results: Among 266 randomized patients (mean age 80.8 years), 9-month OS was 86.5% in the MTX + STS arm and 83.5% in the STS arm [P = 0.498; hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.40–1.50]. The lower limit of the 90% CI for the difference in survival rates (−4.6%) remained within the predefined noninferiority margin, meeting the primary endpoint. Among the 87.4% of patients who achieved disease control within 28 days, relapse occurred in 31 patients in the MTX + STS arm and 52 in the STS arm, corresponding to a 9-month RFS of 68.4% (95% CI 59.3–78.8) vs. 47.4% (95% CI 37.7–59.5), respectively (P = 0.042). SAEs were more frequent in the MTX + STS arm than in the STS arm [mean number per patient per month 0.40 (95% CI 0.23–0.57) vs. 0.19 (95% CI 0.01–0.36), P = 0.005]. One limitation of this study was its open-label design. Moreover, it did not include a validated disease activity score and was conducted in a selected BP population managed under clinical trial conditions. Conclusions: Maintenance therapy with low-dose MTX is noninferior to prolonged STS in terms of survival and is associated with a reduced risk of relapse, at the cost of increased toxicity.
- Open Access
- 14 December 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1392-1405
Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact
Background: Chronic skin diseases such as psoriasis (PSO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are frequently associated with psychological distress, potentially promoting maladaptive coping mechanisms including addictive behaviours. Despite evidence of higher addiction rates among dermatology patients, comprehensive multicenter data across Europe are lacking. Objectives: To estimate the prevalence and patterns of addictive behaviours among patients with chronic skin diseases in European tertiary dermatology centres and explore associated sociodemographic and clinical factors. Methods: This multicentre cross‐sectional study recruited adult patients with PSO, AD, HS, alopecia areata (AA), urticaria, or vitiligo from dermatology departments in 20 European countries. Participants completed a standardized questionnaire assessing sociodemographics, disease characteristics, and addictive behaviours (smoking, alcohol use, drug use, gambling, internet addiction, and eating disorders). Descriptive analyses and multivariate logistic regression were performed. Results: Among 3585 participants (median age 43 years; 51.1% female), the prevalence of addictive behaviours was notable: smoking (25.7%), pathological gambling (4.5%), hazardous drinking (8.8%), alcohol dependence (2.5%), drug use disorders (5.3%), eating disorders (1.8%), and internet addiction (29.7%). Smoking was most common among PSO and HS patients (48.6%), and gambling among AA and vitiligo patients (8.2%). Significant associations included male sex, younger age, single status, higher Dermatology Life Quality Index (DLQI) scores, and regional variation. Discussion: Addictive behaviours are prevalent in dermatology patients and are associated with both sociodemographic and disease‐related factors. The DLQI was positively correlated with multiple addictions, suggesting that reduced quality of life may contribute to maladaptive coping. However, due to the absence of a control group, the tertiary care setting, limited center distribution, and unknown response rate, generalizability is restricted. Conclusions: Addiction screening and supportive mental health strategies should be integrated into dermatologic care, particularly for high‐risk patients. Population‐based studies with control groups are needed to confirm these findings.
- 14 December 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1392-1405
Open AccessAddiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact
Background: Chronic skin diseases such as psoriasis (PSO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are frequently associated with psychological distress, potentially promoting maladaptive coping mechanisms including addictive behaviours. Despite evidence of higher addiction rates among dermatology patients, comprehensive multicenter data across Europe are lacking. Objectives: To estimate the prevalence and patterns of addictive behaviours among patients with chronic skin diseases in European tertiary dermatology centres and explore associated sociodemographic and clinical factors. Methods: This multicentre cross‐sectional study recruited adult patients with PSO, AD, HS, alopecia areata (AA), urticaria, or vitiligo from dermatology departments in 20 European countries. Participants completed a standardized questionnaire assessing sociodemographics, disease characteristics, and addictive behaviours (smoking, alcohol use, drug use, gambling, internet addiction, and eating disorders). Descriptive analyses and multivariate logistic regression were performed. Results: Among 3585 participants (median age 43 years; 51.1% female), the prevalence of addictive behaviours was notable: smoking (25.7%), pathological gambling (4.5%), hazardous drinking (8.8%), alcohol dependence (2.5%), drug use disorders (5.3%), eating disorders (1.8%), and internet addiction (29.7%). Smoking was most common among PSO and HS patients (48.6%), and gambling among AA and vitiligo patients (8.2%). Significant associations included male sex, younger age, single status, higher Dermatology Life Quality Index (DLQI) scores, and regional variation. Discussion: Addictive behaviours are prevalent in dermatology patients and are associated with both sociodemographic and disease‐related factors. The DLQI was positively correlated with multiple addictions, suggesting that reduced quality of life may contribute to maladaptive coping. However, due to the absence of a control group, the tertiary care setting, limited center distribution, and unknown response rate, generalizability is restricted. Conclusions: Addiction screening and supportive mental health strategies should be integrated into dermatologic care, particularly for high‐risk patients. Population‐based studies with control groups are needed to confirm these findings.
- Open Access
- 18 November 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (1) , 188-193
Useful Instruments for Psoriasis Patients’ Follow‐Up in Teleconsultation Setting
Background: Teledermatology may be beneficial for psoriasis management and a working group of the International Psoriasis Council recently outlined the value of patient questionnaires in teledermatology. Objectives: Identify instruments that could optimise psoriasis evaluation when completed before a teleconsultation; assess patients’ and dermatologists’ opinions on the value of teleconsultations for managing psoriasis. Methods: This pilot, cross‐sectional study, conducted in France (November 2021 to February 2022), invited patients with psoriasis and dermatologists experienced in treating psoriasis to complete an electronic survey assessing (1) the value of teleconsultations, (2) the attributes of 12 specific instruments to be used in teleconsultation, and (3) the most important attributes of these instruments. The specific instruments assessed covered three domains: (1) Quality of life (QoL; Dermatology Life Quality Index [DLQI] and SKINDEX), (2) disease severity and involvement (Simplified Psoriasis Index [Sa‐SPI]; self‐evaluations of pruritus, pain and severity on a numeric rating scale [NRS]; self‐evaluations of involved body surface area [BSA]; skin photography), (3) rheumatology (Psoriatic Arthritis Uncluttered Screening Evaluation [PURE], Early ARthritis for Psoriatic patients [EARP], Psoriasis Epidemiology Screening Tool [PEST]). Results: From 100 patients responding, 75 were willing to be followed in a telemedicine setting. The instrument attributes most important to patients were helping overcome teleconsultation limitations and facilitating conversations. From 51 dermatologists responding, 42 were in favour of telemedicine. The instrument attributes most important to dermatologists were clinical relevance and helping overcome teleconsultation limitations. Patients and dermatologists ranked the tools similarly, with DLQI scoring higher than SKINDEX, and Sa‐SPI scoring higher than self‐evaluations of pruritus, pain and severity, self‐evaluations of involved BSA and skin photography. There was no preferred rheumatology questionnaire. Conclusions: Our data suggest DLQI, Sa‐SPI, and a rheumatology questionnaire could be useful to complete and transmit before a dermatology teleconsultation. These findings should be validated in a larger study with global participants.
- 18 November 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (1) , 188-193
Open AccessUseful Instruments for Psoriasis Patients’ Follow‐Up in Teleconsultation Setting
Background: Teledermatology may be beneficial for psoriasis management and a working group of the International Psoriasis Council recently outlined the value of patient questionnaires in teledermatology. Objectives: Identify instruments that could optimise psoriasis evaluation when completed before a teleconsultation; assess patients’ and dermatologists’ opinions on the value of teleconsultations for managing psoriasis. Methods: This pilot, cross‐sectional study, conducted in France (November 2021 to February 2022), invited patients with psoriasis and dermatologists experienced in treating psoriasis to complete an electronic survey assessing (1) the value of teleconsultations, (2) the attributes of 12 specific instruments to be used in teleconsultation, and (3) the most important attributes of these instruments. The specific instruments assessed covered three domains: (1) Quality of life (QoL; Dermatology Life Quality Index [DLQI] and SKINDEX), (2) disease severity and involvement (Simplified Psoriasis Index [Sa‐SPI]; self‐evaluations of pruritus, pain and severity on a numeric rating scale [NRS]; self‐evaluations of involved body surface area [BSA]; skin photography), (3) rheumatology (Psoriatic Arthritis Uncluttered Screening Evaluation [PURE], Early ARthritis for Psoriatic patients [EARP], Psoriasis Epidemiology Screening Tool [PEST]). Results: From 100 patients responding, 75 were willing to be followed in a telemedicine setting. The instrument attributes most important to patients were helping overcome teleconsultation limitations and facilitating conversations. From 51 dermatologists responding, 42 were in favour of telemedicine. The instrument attributes most important to dermatologists were clinical relevance and helping overcome teleconsultation limitations. Patients and dermatologists ranked the tools similarly, with DLQI scoring higher than SKINDEX, and Sa‐SPI scoring higher than self‐evaluations of pruritus, pain and severity, self‐evaluations of involved BSA and skin photography. There was no preferred rheumatology questionnaire. Conclusions: Our data suggest DLQI, Sa‐SPI, and a rheumatology questionnaire could be useful to complete and transmit before a dermatology teleconsultation. These findings should be validated in a larger study with global participants.
- 17 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
- 17 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
- 5 November 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (8) , 592-598
Franco-African paediatric teledermatology: a store-and-forward network
- 5 November 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (8) , 592-598
Franco-African paediatric teledermatology: a store-and-forward network